ID 93Alternative Names: ID 93/AP10-602; ID-93/GLA-SE; ID93 + AP10-602; ID93 + GLA-SE; Tuberculosis vaccine adjuvanted - Aeras/Infectious Disease Research Institute; Tuberculosis vaccine recombinant Mycobacterium tuberculosis protein ID93/adjuvant GLA-SE - Aeras/IDRI
Latest Information Update: 16 Jul 2016
At a glance
- Originator Infectious Disease Research Institute
- Developer Aeras; Infectious Disease Research Institute
- Class Recombinant fusion proteins; Synthetic vaccines; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Tuberculosis